A Study Assessing Efficacy Of Paclitaxel In Combination With Bevacizumab (Avastin) For The Treatment Of Malignant Pleural Effusions (MPEs) In Patients With Non–Small Cell Lung Cancer (NSCLC)

Trial Profile

A Study Assessing Efficacy Of Paclitaxel In Combination With Bevacizumab (Avastin) For The Treatment Of Malignant Pleural Effusions (MPEs) In Patients With Non–Small Cell Lung Cancer (NSCLC)

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Malignant pleural effusion; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top